0001209191-20-034091.txt : 20200603 0001209191-20-034091.hdr.sgml : 20200603 20200603165540 ACCESSION NUMBER: 0001209191-20-034091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200601 FILED AS OF DATE: 20200603 DATE AS OF CHANGE: 20200603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nash Huw M. CENTRAL INDEX KEY: 0001780085 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 20940685 MAIL ADDRESS: STREET 1: C/O STOKE THERAPEUTICS, INC. STREET 2: 45 WIGGINS AVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 PRESTON COURT CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 3 PRESTON COURT CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-01 0 0001623526 Stoke Therapeutics, Inc. STOK 0001780085 Nash Huw M. C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 0 1 0 0 COO & CBO Common Stock 2020-06-01 4 M 0 2107 2.19 A 2107 D Common Stock 2020-06-01 4 S 0 1607 27.0823 D 500 D Common Stock 2020-06-01 4 S 0 500 27.484 D 0 D Employee Stock Option (Right to Buy) 2.19 2020-06-01 4 M 0 2107 0.00 D 2018-12-12 Common Stock 2107 228711 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. /s/ Stephen Tulipano, Attorney-in-Fact 2020-06-03